Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teneobio, Inc.

https://www.teneobio.com/

Latest From Teneobio, Inc.

Amgen Rebuilt R&D Platform To Focus On Speed And Access

The company explained during its recent business review how its R&D organization is pursuing the strategic objectives of improving success rates, reducing cycle times and enabling access to novel drugs. 

Business Strategies Companies

Amgen CEO Bradway On Deals: Good (Smaller) Opportunities Are Vast

Amgen is enthusiastic about deals of all sizes, including a new Arrakis collaboration, and is interested in large transactions like its Otezla buy – but Bradway said right-priced opportunities are fewer and farther between. 

Deals Business Strategies

Multiple Myeloma Bispecifics Vie For Leadership Based On Safety, Combinability

Updates at ASH for bispecifics targeting BCMA, GPRC5D and FcRH5 from Regeneron, Janssen, Pfizer, Roche, AbbVie and Harpoon show monotherapy efficacy, initial combination data and potential safety differentiation.

Clinical Trials ImmunoOncology

Pharma Outlook 2022: What Next After A Year Of Innovation And Growth?

The biopharma industry broke records again in 2021 with the amount of money raised for drug development. After a year of rapid growth, what will 2022 bring for market dynamics and R&D catalysts in biopharma?

Outlook 2022 Growth
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Transgenics
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • OMT Therapeutics Inc
    • Recombinant Antibody Technology (RAT) Ltd.
UsernamePublicRestriction

Register